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Background: Although combined chemotherapy has increased survival rates among chil-
dren with cancer, such treatments can induce sensorineural hearing loss. Therefore, we 
aimed to identify risk factors for hearing impairments in patients with childhood cancer. 
Methods: Audiograms were obtained from 115 patients with childhood cancer and survi-
vors (age ＜20 years). Pure tone audiometry (PTA) was performed at octave intervals 
within the range of 250-8000 Hz. We evaluated clinical risk factors associated with hear-
ing impairments. Hearing loss was evaluated based on the maximal decibel (dB) loss 
in any frequency for each ear (RAmax or LAmax) and weighted mean dB loss for specific 
frequencies (RAavg or LAavg). 
Results: Forty percent of patients (N=46) exhibited hearing loss ＞20 dB based on the 
weighted mean value in either ear. Severe hearing impairments were observed in 56% 
of patients with brain tumors. Although cisplatin or vinca alkaloids were significant risk 
factors for hearing impairment, the use of both cisplatin and vinca alkaloids exhibited 
the highest odds ratio for hearing impairment (P＜0.001, ＜0.001 for R/LAmax; P=0.099, 
0.039 for R/LAavg). Multivariate analysis revealed that the use of both cisplatin and vinca 
alkaloids was an independent risk factor for hearing impairment based on RAmax, LAmax, 
and LAavg (P＜0.001, ＜0.001, 0.039, respectively). 
Conclusion: Our findings indicate that cisplatin and vinca alkaloids exert an additive 
effect on the risk of hearing impairment in survivors of childhood cancer. Further pro-
spective studies are thus required to determine the most effective chemotherapeutic regi-
men for reducing ototoxicity.
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Introduction
Over the past twenty years, survival rates for children 
with malignant tumors have increased due to the advance 
of more effective treatments such as combined chemo-
therapy, as well as improvements in diagnostic methods, 
surgical techniques, and radiation therapy [1]. However, 
children with malignant tumors are also exposed to various 
side effects of chemotherapeutic treatment —which vary 
based on the type of cancer, treatment modalities, chemo-
therapeutic agents, and age at diagnosis —with more than 
60% of survivors experiencing late-onset effects [2,3]. Cura-
tive chemotherapeutic treatments for childhood cancer in-
volving agents such as cisplatin induce sensorineural hear-
ing loss following treatment in up to 85% of patients [1,4]. 
Hearing impairment is one of the most common adverse 
effects in patients with childhood cancer and survivors [5], 
and typically occurs due to ototoxic reactions affecting 
components of the auditory and vestibular system in the 
inner ear. Generally, hearing loss is bilateral, irreversible, 
associated with tinnitus, and begins with the loss of the 
ability to perceive high-frequency auditory stimuli [1,5]. 
Hearing loss affects various aspects of child development 
and may result in psychosocial problems as well as delayed 
development of speech and language; poor educational 
achievement; and impairments in communication, social in-
teraction, and overall quality of life [2].
There are various risk factors for hearing impairments in 
survivors of cancer. Drugs such as antineoplastic agents, 
aminoglycosides, nonsteroidal anti-inflammatory drugs, an-
tibiotics, diuretics, and anti-hypertensive agents have been 
associated with hearing impairments and ototoxicity leading 
to hearing loss [6]. Moreover, chemotherapeutic agents 
such as doxorubicin, vincristine, cyclophosphamide, gemci-
tabine, and oxaliplatin are ototoxic [5,6]. Platinum agents 
such as cisplatin and carboplatin generate the most severe 
auditory symptoms, including tinnitus and changes in audi-
tory sensitivity [5-8]. Radiotherapy, which accelerates the 
destruction of tumor cells via ionizing radiation beams, can 
also damage the auditory organs and related brain struc-
tures. Hearing loss is most common during radiotherapy for 
tumors of the head and neck [9,10]. Previous studies have 
reported that, when cranial radiotherapy is utilized as the 
only treatment modality, ototoxicity occurs only when the 
dosage exceeds 32 Gray (Gy) in cochlear structures [2]. 
However, combined chemotherapy and radiation cause 
worse ototoxicity than either one alone. Nevertheless radia-
tion therapy is limited to most of brain tumors. 
In the present study, we aimed to investigate hearing im-
pairments in patients with childhood cancer and survivors 
according to clinical risk factors such as the type of cancer, 
classes of chemotherapeutic agents, and other treatment 
modalities utilized, based on standard medical practices in 
Korea. 
Materials and Methods
1) Study population
The present study included 115 patients with childhood 
cancer and survivors of childhood cancer (age under 20 
years) who had been diagnosed and treated at the Yonsei 
Cancer Center of the Yonsei University Health System in 
Seoul, Korea from January of 1993 to December of 2014. 
We established the Long-Term Follow-Up Clinic (LTFC) 
for survivors of childhood cancer in 2004, at which patients 
of the present study underwent follow-up assessment. 
Audiograms were recommended for the survivors based on 
treatment type and medical history. Follow-up procedures 
and schedules were developed in accordance with Korean 
standards and institutional guidelines, as described in pre-
vious reports [11,12]. Consent to perform an audiogram was 
obtained from 115 patients. All patients were regarded as 
survivors of childhood cancer, based on survival in the ab-
sence of disease for over 2 years following the completion 
of treatment. Among the study population, 79.1% (91/115) 
were survivors at the time of the audiogram, while the re-
maining patients underwent evaluation for 2 years follow-
ing the completion of treatment. This study was approved 
by institutional review board of Severance Hospital, Yonsei 
University Health System (4-2017-6000).
2) Audiometry
Pure-tone audiometry (PTA) was performed at octave in-
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Table 1. Characteristics of survivors of childhood cancer 
Characteristics
Values 
(median, IQR)
Age at diagnosis (years) 4.9 (2.1-8.5)
Age at treatment completion (years) 6.4 (3.5-10.0)
Time since after completion (years) 10.1 (6.9-13.5)
Age at audiogram (years) 5.8 (4-10)
Time from completion to audiogram (years) 4.8 (2.3-8.3)
Gender (M:F) 63:52
Diagnosis N (%)
  Leukemia/lymphoma 28 (24.4%) 
  Brain tumor 41 (35.7%)
  Neuroblastoma 14 (12.2%)
  Wilms tumor 2 (1.7%)
  Hepatoblastoma 7 (6.1%)
  Germ cell tumor 6 (5.2%)
  Sarcoma 12 (10.4%)
  Others 5 (4.3%)
Treatment modalities N (%)
  Chemotherapy 114 (99.1%)
  Radiotherapy 68 (59.1%)
  Surgery 82 (71.3%)
  Hematopoietic stem cell Transplantation 34 (29.6%)
tervals within the range of 250-8000 Hz, and the loss of 
hearing threshold was expressed in decibels (dB) at each 
frequency. Maximal dB loss at any frequency was defined 
in each ear (RAmax for right ear and LAmax for left ear). The 
weighted mean dB loss for audible frequencies was calcu-
lated and defined as RAavg for the right ear and LAavg for 
the left ear, as follows: [dB at 500 Hz＋(dB at 1000 Hz× 
2)＋(dB at 2000 Hz×2)＋dB at 4000 Hz]/6. 
We analyzed the association between hearing loss and 
clinical risk factors such as age, gender, diagnosis, class of 
chemotherapeutic agents, use of radiotherapy, hemato-
poietic stem cell transplantation, etc. The severity of impair-
ment was defined as follows: mild, ＜20 dB loss; moderate: 
20 to 40 dB loss; severe: 40 to 60 dB loss; and profound: 
＞60 dB loss. The presence of hearing impairment was de-
fined as ＞20 dB loss in maximal and weighted mean levels 
of hearing. 
3) Statistical notes
To evaluate the effect of diagnosis on hearing loss, we 
classified diagnoses into three groups: brain tumors, hema-
tologic malignancies, and other solid tumors. Chemothera-
peutic agents were classified based on general cytotoxicity, 
with the exception of platinum agents. Categorical varia-
bles, including diagnoses and treatment types, were ana-
lyzed using chi-square tests. Continuous variables were 
compared using Student’s t-tests for parametric analyses 
and Mann–Whitney U-tests for non-parametric analyses. 
Multivariate logistic regression analysis was performed to 
examine the association between clinical risk factors and 
hearing impairment: severe impairment based on maximal 
dB loss at any frequency in either ear (RAmax ＞60 dB and 
LAmax ＞60 dB) and weighted mean dB loss in audible fre-
quencies for either ear (RAavg ＞20 dB, and LAavg ＞20 dB). 
SPSS version 23 for Windows (SPSS, Inc., Chicago, IL, USA) 
was used for the statistical analysis of each outcome 
measure.
Results
1) Characteristics of survivors
The present study included 63 male patients and 52 fe-
male patients, with a mean age at diagnosis of 5.8±4.6 
years old. Median age at diagnosis was 4.9 years (interquar-
tile range [IQR]: 2.1-8.5 years) (Table 1). Brain tumor (N=41, 
35.7%) was the most common diagnosis. 
2) Prevalence of hearing impairment
Among the 115 included patients, hearing impairment 
was observed in the right (RAmax ＞20 dB) and left ear 
(LAmax ＞20 dB) in 63.5% (N=73) and 67.8% (N=78) of pa-
tients, respectively. When hearing impairment was defined 
based on the weighed mean of dB loss, 32.2% (N=37) of 
patients exhibited hearing loss in the right ear (RAavg ＞20 
dB), while 40.0% (N=46) of patients exhibited hearing loss 
in the left ear (LAavg ＞20 dB). Median RAmax was 40 dB 
(IQR: 15-75), while median LAmax was 35 dB (IQR: 15-80). 
Median RAavg was 11.6 dB (IQR: 5.8-24.1), and median 
LAavg was 12.5 dB (IQR: 6.6-26.6). Median age at diag-
nosis (ages 3, 7.5, and 10 years old) was not identified as 
a risk factor for hearing impairment based on either max-
imal or weighted mean dB loss ＞20 dB. Forty percent of 
patients (N=46) exhibited hearing loss ＞20 dB based on 
the weighted mean value in either ear. Severe hearing im-
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Fig. 1. Comparison of hearing impairments based on loss of decibels (dB) in hearing threshold according to clinical risk factors. (A1-4) 
Risk according to use of chemotherapeutic agents: none, either cisplatin or vinca alkaloids, and both use of cisplatin and vinca 
alkaloids. (B1-4) Risk according to diagnosis: hematologic malignancies, brain tumors, or other solid tumors. P-value means linear 
by linear association. cis, cisplatin; Vinca, vinca alkaloids; hema, hematologic malignancies; brain, brain tumors; solid, other solid 
tumors; RAmax, maximal dB loss of thresholds at any frequency in the right ear as determined via pure tone audiometry; LAmax, maximal 
dB loss in the left ear; RAavg, weighted mean dB loss of thresholds in the right ear; LAavg, weighted mean dB loss in the left ear.
pairments were observed in 56% of patients with brain 
tumors.
3) Clinical risk factors for maximal dB loss
Cranial radiation ＞5,000 cGy was identified as a sig-
nificant risk factor for RAmax but not for LAmax (P=0.011, 
0.088, respectively) (Table 2). Although cisplatin was iden-
tified as a risk factor for both RAmax and LAmax (P＜0.001, 
＜0.001 respectively), carboplatin was not identified as a 
significant risk factor for either RAmax or LAmax (P=0.478, 
0.749, respectively). Among cisplatin users, 63.5% and 
67.8% exhibited hearing loss in the right and left ear, re-
spectively (data not shown). The use of vinca alkaloids was 
identified as an adverse factor for both RAmax and LAmax 
(P=0.002, 0.002, respectively). Among cisplatin users, the 
odds ratio for severe hearing loss based on maximal dB 
loss in the right ear (RAmax ＞60 dB) was 32.9 (10.99-98.51) 
(P＜0.001), while that based on maximal dB loss in the left 
ear (LAmax ＞60 dB) was 22.5 (8.1-62.61) (P＜0.001), re-
spectively.
4) Clinical risk factors for weighted mean dB loss
Among those who had received treatment with vinca al-
kaloids, RAavg was 12.9 dB (IQR: 6.0-30.4), and LAavg was 
14.1 (IQR: 7.5-32.9), respectively (Table 2). In contrast, 
RAavg and LAavg values were 7.5 dB (IQR: 5.0-15.0) (P= 
0.133) and 7.5 dB (IQR 5.0-13.3) (P=0.065) for those who 
did not undergo treatment with vinca alkaloids, respec-
tively. Patients treated with cisplatin exhibited RAavg values 
of 17.5 dB (IQR 8.3-35.8) and LAavg values of 17.5 dB (IQR 
10.8-42.5), whereas, RAavg and LAavg values for patients 
who did not undergo treatment with cisplatin were 6.6 dB 
(IQR 4.1-11.4) (P＜0.001) and 7.5 dB (IQR 3.3-13.1) (P＜ 
0.001), respectively. 
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5) Additive effect of cisplatin and vincristine on hearing 
impairment
Among those who had received combined treatment 
with cisplatin and vincristine, 84.6% and 80.8% exhibited 
hearing loss ＞60 dB for both RAmax and LAmax, respectively; 
however, normal audiometry results were observed in 
50.0% and 62.5% of patients who did not receive treatment 
with either of these agents, for RAmax and LAmax, re-
spectively (P＜0.001 and ＜0.001, by linear by linear asso-
ciation, respectively; Fig. 1A-1 and 2). Among users of both 
cisplatin and vincristine, RAavg and LAavg ＞60 dB were ob-
served in 15.4% and 13.5% of patients, respectively; how-
ever, normal audiometry results were observed 81.3% and 
93.8% of patients who did not receive treatment with either 
of these agents (P＜0.001 and 0.001 by linear by linear as-
sociation, Fig. 1A-3 and 4).
6) Association between diagnosis and severity of hearing 
impairment
Maximal dB loss ＞60 dB was observed in more than 
50% of patients with brain/other solid tumors (RAmax, P＜ 
0.001; LAmax, P＜0.001, by linear by linear association, re-
spectively; Fig. 1B-1 and 2).
7) Multivariate analysis
For RAmax ＞60 dB and LAmax ＞60 dB, the use of cispla-
tin and vinca alkaloids was a significant risk factor for hear-
ing impairment, with odds ratios of 65.21 (P=0.001) and 
147.4 (P=0.001), respectively (Table 3). For RAavg ＞20 dB 
and LAavg ＞20 dB, use of both cisplatin/vinca alkaloids ex-
hibited odds ratios of 3.64 (P=0.099) and 10.06 (P=0.039), 
respectively. Antibiotic use was identified as a favorable 
factor for hearing impairment with regard to both RAmax ＞
60 dB and LAmax ＞60 dB (P=0.004, ＜0.001, respectively). 
Radiotherapy consisting of ＞5,000 cGy targeted toward the 
head region was not identified as an independent risk fac-
tor for hearing impairment (RAmax ＞60 dB, P=0.692; LAmax 
＞60 dB, P=0.178).
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Discussion
In the present study, we identified treatment regimens 
involving platinum agents or vinca alkaloids as significant 
risk factors for hearing impairment in survivors of child-
hood cancer. The poorest hearing outcomes were observed 
in patients who had undergone treatment with both cispla-
tin and vinca alkaloids, compared with those who had un-
dergone treatment with one or none of these chemo-
therapeutic agents. According to a 2012 report by the 
World Health organization (WHO), approximately 16 mil-
lion children worldwide (range: 12-26 million) live with 
hearing loss ＞35 dB, and the estimated global prevalence 
of hearing loss ＞35 dB in children 5 to 14 years of age 
is 1.4% [13,14]. However, the rate of hearing impairment 
in the present study was significantly higher, as hearing loss 
was observed in over 40% of included patients. 
A previous study regarding cisplatin-induced hearing loss 
reported that 64% of the 55 included patients who had re-
ceived cisplatin treatment developed hearing impairment, in 
accordance with rates of 63.5-67.8% observed in the pres-
ent study [15]. However, Chang et al. reported that hearing 
loss occurred in 52.2% of included patients who had under-
gone treatment with cisplatin (N=35/67) [16], which is lower 
than those showed in present study. Nonetheless, our study 
included only 11 patients who had undergone treatment 
with cisplatin only, which may have resulted in this 
discrepancy. Among users of both cisplatin and vinca alka-
loids, 90.4% exhibited hearing loss in each ear, which sig-
nificantly affected the proportion of cisplatin users exhibit-
ing hearing loss in our cohort. In addition, inconsistencies 
in the reported rates of hearing impairment among studies 
may be due to differences in the combination of treatment 
agents, age, diagnosis, use of radiotherapy, cumulative 
doses, and other factors [17].
Previous studies have further reported that the incidence 
of platinum-related hearing impairment increases along 
with increases in cumulative dose [17]. Different dosing for-
mulas, such as dose per kilogram of bodyweight or body 
surface area, may thus influence these effects. Moreover, 
research has indicated that bolus injections of chemo-
therapeutic agents are more ototoxic than doses provided 
over a longer duration [17]. Cisplatin ototoxicity manifests 
as mild yet permanent bilateral hearing loss, affecting 
10-25% of adults and 26-90% of children [18]. In our study, 
cisplatin and carboplatin induced severe hearing impair-
ment in 54.7% and 35.6% of patients, respectively. Cochlear 
toxicity associated with platinum is due to interference with 
signal transduction in the cochlea [18]. The risk factors for 
ototoxicity in cisplatin include patient age at treatment, cu-
mulative dose of cisplatin, prior hearing impairments, dos-
ing schedule, concomitant use of aminoglycosides, and cra-
nial irradiation [18]. Carboplatin is an analog of cisplatin, 
which was developed to reduce the dose-limiting toxicity 
of cisplatin. However, large doses of carboplatin can dam-
age the outer hair cells after the destruction of all inner hair 
cells in the ear, thereby leading to hearing impairment [19].
Neuropathy is a well-known dose-limiting side effect of 
vincristine that can manifest as peripheral, cranial, or auto-
nomic neuropathy. Peripheral neuropathy commonly pres-
ents as neuropathic pain, loss of deep tendon reflexes, 
wrist and foot drop, and paresthesia. Less commonly, cra-
nial nerve palsies such as jaw pain, oculomotor nerve dys-
function, facial palsy, and laryngeal nerve paresis have 
been observed following treatment with vincristine [20]. In 
our study, vincristine was identified as a significant factor 
for hearing impairment. While use of either cisplatin or vin-
cristine alone was a risk factor for hearing impairment, the 
use of both chemotherapeutic agents significantly increased 
the risk of hearing impairment. To our knowledge, the 
present study is the first to report an additive effect of cis-
platin and vinca alkaloids on the risk for hearing impair-
ment in survivors of childhood cancer. In our study, vin-
cristine combined with cisplatin may potentiate neurologic 
damage in children with brain tumors or sarcoma. 
Our findings also indicated that treatment with actino-
mycin or antimetabolite served as a favorable factor. 
However, such findings do not indicate that these agents 
exert protective effects against hearing damage, but instead 
reflect the close association between chemotherapeutic 
agents and the treatment regimen for specific diagnoses. 
Actinomycin is typically used in combination with vincris-
tine, and cyclophosphamide. In contrast, cisplatin-contain-
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ing regimens usually exclude actinomycin. 
In our study, radiation therapy alone was not identified 
as a significance risk factor, although the risk of hearing 
loss increased with the addition of cisplatin or vinca 
alkaloids. Radiation to the cochlea can lead to sensorineural 
hearing impairment [1], as histopathologic changes due to 
radiation therapy often lead to inner ear damage [21]. To 
reduce late toxicity, treatment should aimed to reduce the 
volume of normal tissue exposed to radiation [22]. 
Diagnosis alone was also not identified as a significant 
risk factor, likely due to the application of specific treat-
ment modalities and regimens for specific diagnoses. For 
example, cisplatin is more frequently used in the treatment 
of brain tumors, neuroblastoma, gynecological cancer, germ 
cell tumors, and sarcoma than in that for other tumor types 
[23]. Our findings suggest that the treatment regimen should 
be modified in patients at risk for severe ototoxicity. While 
our results indicate that simultaneous use of vincristine and 
cisplatin should be avoided, further studies are required to 
determine whether this approach effectively reduces oto-
toxicity without affecting mortality. 
The present study possesses several limitations of note. 
First, this study was a retrospective analysis of a heteroge-
neous study population based on diagnosis and involved 
only a small number of survivors who had completed au-
diometry assessments. Moreover, we did not perform 
long-term follow-up assessments to determine whether fur-
ther impairments or improvements in hearing loss had 
occurred. In addition, we were unable to examine the in-
fluence of age on hearing impairment due to the limited 
number of patients. Also, we did not examine the effect 
of cumulative doses of these agents on hearing impairment. 
Nonetheless, our findings indicate that cisplatin and vinca 
alkaloids exert an additive effect on the risk of hearing im-
pairment when they were used in combination in survivors 
of childhood cancer. Further prospective studies are thus 
required to determine the most effective chemotherapeutic 
regimen for reducing ototoxicity.
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